Clinical Trial Update: Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating HRS-1167 with Famitinib ± Camrelizumab in germline BRCA-mutated, HER2-negative breast cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Famitinib (Famitinib)
• HRS-1167

Snippet

Sponsor: Fudan University | Conditions: BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer | Phase 2 | Status: RECRUITING